1. Background {#sec1-biomolecules-09-00233}
=============

The majority of HIV-infected individuals on combination antiretroviral therapy (cART) achieve undetectable levels of plasma HIV-RNA, recover CD4^+^ T-cell levels in peripheral blood, and restore many immunological functions \[[@B1-biomolecules-09-00233],[@B2-biomolecules-09-00233]\]. However, a significant number of cART-treated patients fail to achieve substantial increases in the CD4^+^ T-cell count, remaining at risk of progression to acquired immune deficiency syndrome (AIDS), non-AIDS morbidities, and death \[[@B3-biomolecules-09-00233],[@B4-biomolecules-09-00233],[@B5-biomolecules-09-00233]\].

The underlying mechanisms to this phenomenon are complex and likely multifactorial, including clinical features, such as age \[[@B6-biomolecules-09-00233]\], hepatitis coinfection \[[@B7-biomolecules-09-00233]\], severe immunodeficiency at the time of cART initiation \[[@B8-biomolecules-09-00233]\], or a low CD4^+^ T-cells nadir \[[@B9-biomolecules-09-00233]\]. Among the immunological factors associated with a poor restoration of CD4^+^ T-cells, chronic immune activation \[[@B10-biomolecules-09-00233]\], levels of T-cell apoptosis \[[@B8-biomolecules-09-00233]\], and reduced thymic output \[[@B11-biomolecules-09-00233]\] have already been described.

Furthermore, genetic factors have been related to CD4 T-cell restoration after virological suppression, among them specific mitochondrial haplogroups \[[@B12-biomolecules-09-00233]\] and polymorphisms in genes encoding cytokines or cytokine receptors \[[@B13-biomolecules-09-00233],[@B14-biomolecules-09-00233],[@B15-biomolecules-09-00233]\]. Taken together, all these factors could potentially be employed to predict impaired CD4 T-cell recovery and avoid clinical complications. Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) are essential factors for T cell homeostasis by promoting development, survival, proliferation, and de novo production of T and B lymphocytes \[[@B16-biomolecules-09-00233]\]. Besides, IL-7 has been described as a critical factor for CD4^+^ T-cells recovery in HIV-infected patients on cART \[[@B17-biomolecules-09-00233]\]. IL-7R is a heterodimer formed by the common cytokine receptor γ-chain (CD132) and the α-chain specific of the IL-7 receptor (IL7Rα or CD127) \[[@B16-biomolecules-09-00233]\]. Polymorphisms in *IL7RA*, the gene encoding for IL7Rα, have previously been associated with rapid progression to AIDS \[[@B18-biomolecules-09-00233]\] and with CD4^+^ T-cell recovery after initiation of cART, especially the missense polymorphism rs6897932 \[[@B19-biomolecules-09-00233],[@B20-biomolecules-09-00233],[@B21-biomolecules-09-00233],[@B22-biomolecules-09-00233]\]. The *IL7RA* rs6897932 Single Nucleotide Polymorphism (SNP) is a missense variant located at the *IL7RA* gene, within the alternatively spliced exon 6. This change (C/T) causes a substitution of threonine with isoleucine (Ile244) in the transmembrane region of the protein \[[@B23-biomolecules-09-00233]\]. The C allele is related to alternative splicing of IL7RA that promotes an increase of the ratio between soluble IL7RA (sIL-7Rα) and membrane-bound IL-7RA (mIL-7Rα) \[[@B21-biomolecules-09-00233],[@B23-biomolecules-09-00233],[@B24-biomolecules-09-00233]\]. However, no studies so far have analyzed the potential impact of this polymorphism on CD4^+^ T-cell restoration in a particular population of patients starting cART with very low CD4^+^ T-cell counts, a population of patients that is growing due to late HIV diagnosis \[[@B9-biomolecules-09-00233]\] and in whom the prevalence of impaired CD4 restoration is very high \[[@B8-biomolecules-09-00233]\].

2. Objective {#sec2-biomolecules-09-00233}
============

We aimed to analyze the association between *IL7RA* rs6897932 SNP and CD4^+^ T-cell count gain in naïve patients infected with HIV who started cART with very low CD4^+^ T-cell counts (\<200 cells/mm^3^).

3. Methods {#sec3-biomolecules-09-00233}
==========

3.1. Study Population {#sec3dot1-biomolecules-09-00233}
---------------------

We performed a retrospective study in 411 HIV-infected patients starting cART included in two different cohorts: The majority of patients came from the Spanish AIDS Research Network cohort (CoRIS); the rest of the patients came from the AIDS Research Institute IrsiCaixa-HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (Barcelona, Spain) cohort. All subjects provided informed consent to participate in the study, and the study protocol was approved by the Fundación Jiménez Díaz Ethics Committee in concordance with the Declaration of Helsinki (approval date: 26 May 2015; record number: PIC 52/2015_FJD). The inclusion criteria were: (i) Naïve for cART at inclusion in the cohort; (ii) plasma HIV-RNA \> 200 copies/mL; (iii) starting cART with CD4^+^ T-cells count \< 200 cells/mm^3^; (iv) complete viral suppression (plasma HIV-RNA \< 50 copies/mL) for two years after starting cART; (v) regular follow up of CD4^+^ T-cells count and plasma HIV-RNA for two years after starting cART; and (vi) DNA sample available for genotyping ([Figure 1](#biomolecules-09-00233-f001){ref-type="fig"}). From a total of 6160 HIV-infected patients included in the CoRIS and HIVACAT cohorts, 411 patients meeting all the inclusion criteria were analyzed.

Clinical data from each patient were collected from medical records, which included demographic, clinical, virological, and laboratory data. Gender was assessed by self-identification and there were no transgender individuals. Time since HIV diagnosis was the time since the first blood test positive for HIV. The mode of transmission was recovered from the medical record of the patients and was inferred from the history of intravenous drugs use and of sexual behavior. Hepatitis B and Hepatitis C coinfection were determined by a clinical test. The clinical management of patients during follow-up was performed according to clinical guidelines.

3.2. DNA Genotyping {#sec3dot2-biomolecules-09-00233}
-------------------

Samples were processed and frozen immediately after their reception in the HIV HGM BioBank (<http://hivhgmbiobank.com/?lang=en>). Total DNA isolation was performed from peripheral blood mononuclear cells with Qiagen columns (QIAamp DNA Blood Midi/Maxi; Qiagen, Hilden, Germany). DNA samples were genotyped at the Spanish National Genotyping Center (CeGen; <http://www.cegen.org/>) using the iPLEX^®^ Gold technology and Sequenom's MassARRAY platform (San Diego, CA, USA).

3.3. Outcome Variables {#sec3dot3-biomolecules-09-00233}
----------------------

The study period was 24 months. The primary outcome was the change in values of CD4^+^ T-cells during the follow-up. The outcome variables analyzed were of two types: a) Continuous: Slope of CD4^+^ T-cells and change in CD4^+^ T-cells (ΔCD4^+^) during follow-up; and CD4^+^ T-cells count at the end of follow-up; b) dichotomous: slope of CD4^+^ T-cells ≥10 and ≥15 CD4^+^ T-cells/mm^3^/month; increases of ≥200, ≥300, ≥400, and ≥500 CD4^+^ T-cells/mm^3^; and CD4^+^ T-cells at the end of follow-up ≥350 and ≥500 CD4^+^ T-cells/mm^3^.

3.4. Statistical Analysis {#sec3dot4-biomolecules-09-00233}
-------------------------

Statistical analysis was performed with Statistical Package for the Social Sciences (SPSS) software (version 22.0, SPSS INC, Chicago, IL, USA). All tests were two-tailed with *p*-values \< 0.05 considered significant. Categorical data and proportions were analyzed by using a Chi-squared test or Fisher´s exact test. Mann--Whitney U test was used to compare data between independent groups when the variables were continuous. *IL7RA* rs6897932 SNP was evaluated for Hardy--Weinberg equilibrium (HWE) by Chi-square test, considering equilibrium when *p* \> 0.05. We used the generalized linear model (GLM) to analyze the genetic association between *IL7RA* rs6897932 SNP and outcome variables. Specifically, a GLM with a gamma distribution (log-link) was used for continuous variables, and a GLM with a binomial distribution (logit-link) was used for dichotomous variables. These tests provide the differences between groups, the arithmetic mean ratio (AMR), and the odds ratio (OR). The multivariate regression tests were adjusted by the main clinical characteristics at baseline: (i) Dichotomous variables: Gender, HIV transmission by intravenous drugs use (IDU), hepatitis C and hepatitis B coinfection, cART regimen with protease inhibitors (PI), and Caucasian origin; (ii) continuous variables: Age, time since HIV diagnosis, and baseline CD4^+^ T-cells/mm^3^. Additionally, *p*-values were corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg (*q*-values) procedure to reduce the risk of spurious results.

4. Results {#sec4-biomolecules-09-00233}
==========

4.1. Characteristics of the Study Population {#sec4dot1-biomolecules-09-00233}
--------------------------------------------

The baseline characteristics of patients stratified by *IL7RA* rs6897932 genotypes are shown in [Table 1](#biomolecules-09-00233-t001){ref-type="table"}. Of the total group of patients meeting the inclusion criteria, 256 subjects carried the CC genotype, while 155 carried the CT/TT genotype. Patients carrying the CT/TT genotype had a higher percentage of male (*p* = 0.023) and of subjects of Caucasian origin (*p* = 0.002) but these variables were included in the multivariate models. No significant differences were observed between both groups of patients for the rest of the epidemiological and clinical features analyzed.

4.2. IL7RA rs6897932 Polymorphism and CD4^+^ T-Cells Recovery {#sec4dot2-biomolecules-09-00233}
-------------------------------------------------------------

The rs6897932 SNP displayed \<5% of missing values and was in Hardy--Weinberg equilibrium (*p* = 0.550). The frequency of the C allele was 79.4% and that of the T allele was 20.6%, which were in accordance with the NCBI SNP database (<https://www.ncbi.nlm.nih.gov/snp/rs6897932>). Thus, in the general European population, the rs6897932 T allelic frequency was 27.1% in the 1000 Genomes Project phase3 (1000Genomes) and 28.2% in the genome Aggregation Database (gnomAD-Genomes).

[Table 2](#biomolecules-09-00233-t002){ref-type="table"} shows the association between rs6897932 SNP and CD4^+^ T-cell recovery (full data of GLM models in the [Supplementary file](#app1-biomolecules-09-00233){ref-type="app"}). Overall, the increases in CD4^+^ T-cells were higher in patients carrying rs6897932 CT/TT genotype (CT/TT versus CC). Thereby, in the adjusted analysis, patients carrying rs6897932 CT/TT genotype had a higher slope of CD4^+^ T-cells (AMR = 1.16; *p* = 0.016), a higher CD4^+^ T-cells increase (AMR = 1.19; *p* = 0.004), and a higher CD4^+^ T-cells count at the end of follow-up (AMR = 1.13; *p* = 0.006). Besides, patients carrying rs6897932 CT/TT had a higher odds of having a slope of CD4^+^ T-cells ≥10 CD4^+^ T-cells/mm^3^/month (OR = 1.75; *p* = 0.010) and ≥15 CD4^+^ T-cells/mm^3^/month (OR = 1.94; *p* = 0.015); a CD4^+^ T-cells increase ≥200 CD4^+^ T-cells/mm^3^ (OR = 1.63; *p* = 0.036), ≥300 CD4^+^ T-cells/mm^3^ (OR = 1.63; *p* = 0.025), ≥400 CD4^+^ T-cells/mm^3^ (OR = 1.63; *p* = 0.047), and ≥500 CD4^+^ T-cells/mm^3^ (OR = 2.16; *p* = 0.018); and a value of CD4^+^ T-cells at the end of follow-up ≥500 CD4^+^ T-cells/mm^3^ (OR = 2.44; *p* = 0.006). These *p*-values were corrected for multiple testing using the false discovery rate (FDR) with the Benjamini and Hochberg procedure, and after doing this correction, the statistical significance was lost only for the outcome variable of CD4^+^ T-cells increase ≥400 CD4^+^ cells/mm^3^ (*q*-value = 0.052).

5. Discussion {#sec5-biomolecules-09-00233}
=============

In this study, HIV-infected patients carrying *IL7RA* rs6897932 CT/TT genotype had a better CD4^+^ T-cell count recovery after starting cART with \<200 CD4 T-cells/mm^3^. This association was found for almost all the outcome variables analyzed, both in the univariate and in the multivariate analysis adjusted by the main baseline characteristics. It should be noted that a large number of outcome variables, both continuous and dichotomous, were analyzed, which reflect different effects of immune reconstitution.

Our study supports the positive impact of rs6897932 T allele on CD4^+^ T-cell count recovery in cART-treated patients, in agreement with previous studies performed in cohorts of patients with different ethnicity and different inclusion criteria \[[@B19-biomolecules-09-00233],[@B20-biomolecules-09-00233],[@B22-biomolecules-09-00233]\]. The study of Guzmán-Fulgencio et al. \[[@B19-biomolecules-09-00233]\] was performed in the Spanish population, but we want to emphasize some significant differences concerning our study. In the previous report of Guzmán-Fulgencio et al. \[[@B19-biomolecules-09-00233]\], they studied a cohort of HIV-infected patients who had baseline CD4^+^ T-cells values \<350 cells/mm^3^, from a single Spanish reference hospital, and with a non-uniform follow-up. In the current study, we analyzed a sample more representative of the Spanish population (our cohort of patients infected with HIV came from a large number of hospitals spread throughout Spain), we applied a more restricted inclusion criteria (all patients included had a baseline CD4^+^ T-cell count \<200 cells/mm^3^ and undetectable plasma HIV-RNA during the whole follow-up period), and the follow-up period was the same in all patients (24 months after starting cART). In addition, the statistical analysis applied was different in both studies. In the report of Guzmán-Fulgencio et al. \[[@B19-biomolecules-09-00233]\], a survival analysis was performed with CD4^+^ T-cell count \>500 cells/mm^3^ as the primary outcome, whereas in the present study, we evaluated the changes in the CD4^+^ T-cell count during a period of 24 months and used different threshold values to evaluate the degree of CD4^+^ T-cells reconstitution.

The *IL7RA* rs6897932 C allele has been associated to an increase of the ratio between sIL-7Rα and mIL-7Rα \[[@B21-biomolecules-09-00233],[@B23-biomolecules-09-00233],[@B24-biomolecules-09-00233]\], leading to a reduction of the bioavailability of IL-7 and limiting its effects \[[@B25-biomolecules-09-00233]\]. By contrast, rs6897932 T allele has been associated with lower plasma levels of sIL-7Rα \[[@B21-biomolecules-09-00233],[@B23-biomolecules-09-00233],[@B24-biomolecules-09-00233]\], without limiting the effect of circulating IL-7 \[[@B25-biomolecules-09-00233]\]. Besides, in an in vitro model, Lundtoft et al. identified a dominant effect of the protective *IL7RA* haplotype tagged by rs6897932 on mIL-7Rα expression, whereas the risk *IL7RA* haplotype mainly affected the sIL-7Rα \[[@B26-biomolecules-09-00233]\]. In HIV-infected patients, rs6897932 CC genotype is associated with higher plasma levels of sIL7RA \[[@B21-biomolecules-09-00233],[@B24-biomolecules-09-00233]\], whereas rs6897932 TT genotype is related to lower plasma levels of sIL7RA \[[@B21-biomolecules-09-00233],[@B24-biomolecules-09-00233]\]. Since the CD4^+^ T-cell count recovery is predominantly driven by increases in CD4^+^CD127^+^ T cells in HIV-infected patients on cART \[[@B27-biomolecules-09-00233]\], rs6897932 T carriers may have an advantage because the IL-7 bioavailability is increased. Moreover, in a recent article, Hartling et al. \[[@B28-biomolecules-09-00233]\] also suggested that the effect of rs6897932 is driven by an increased response of IL-7R to IL-7 in patients with TT genotype, which is in line with a faster CD4^+^ T-cell recovery in carriers of the T allele \[[@B19-biomolecules-09-00233],[@B20-biomolecules-09-00233],[@B21-biomolecules-09-00233]\]. Thus, the TT genotype was associated with increased signal transduction and proliferation in response to IL-7 among HIV-infected individuals \[[@B28-biomolecules-09-00233]\]. As discussed above, the rs6897932 T allele, versus C allele, may confer lower sIL-7Rα levels, higher IL-7 bioavailability, and higher capacity of CD4^+^ T-cell recovery, leading to a greater immune response against HIV infection. However, in our study, we did not have any direct functional measurements of *IL7RA* rs6897932 SNP to provide additional data on the potential mechanism.

Our data suggest that *IL7RA* rs6897932 SNP may have an impact on clinical practice in the population of HIV-infected patients beginning cART with very low CD4^+^ T-cell count, a population that is growing due to delayed HIV diagnosis \[[@B9-biomolecules-09-00233],[@B29-biomolecules-09-00233]\] and in whom impaired CD4 restoration is widespread \[[@B8-biomolecules-09-00233],[@B30-biomolecules-09-00233]\]. Thus, the CT/TT genotype is related to the immunological responders (IRs) patients that may recover CD4^+^ T-cell counts to optimal levels 24 months after starting cART, whereas the CC genotype is related to the immunological non-responders (INRs) patients that present a low increase in CD4 T-cell counts despite successful cART and viral suppression. *IL7RA* rs6897932 SNP may help to identify those patients who are at a higher risk of being INR in whom implementation of adjuvant therapies may be needed to improve immune reconstitution and to prevent disease progression and death.

6. Study Limitations {#sec6-biomolecules-09-00233}
====================

Various limitations of our study need to be taken into account. Firstly, the retrospective design may impose a selection bias and prevent the inclusion of other potential confounding variables. Secondly, the limited sample size may have impaired the ability to detect less robust associations. Thirdly, this study was mostly carried out on Caucasian subjects and our conclusions are only truly applicable to this population.

7. Conclusions {#sec7-biomolecules-09-00233}
==============

In summary, the *IL7RA* rs6897932 CT/TT genotype was related to a better CD4^+^ T-cell count recovery after 24 months of therapy in HIV-infected patients who started cART with a CD4^+^ T-cell count \<200 cells/mm^3^. Therefore, our findings could provide information to improve the management of HIV-infected patients with poor prognosis of CD4^+^ T-cell recovery.
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![Diagram of inclusion criteria of patients. This picture shows the inclusion criteria and the sequential strategy of selection of patients included in the study. "*n*" indicates the number of patients selected after each step during filtering process.](biomolecules-09-00233-g001){#biomolecules-09-00233-f001}
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###### 

Clinical and epidemiological characteristics at baseline of HIV infected patients who started combination antiretroviral therapy with very low CD4^+^ T-cells count (\<200 cells/mm^3^).

  Characteristics                                      All Patients    *IL7RA* rs6897932 Genotypes                   
  ---------------------------------------------------- --------------- ----------------------------- --------------- -----------
  No.                                                  411             256                           155             
  Male (n = 411) (%)                                   323 (78.6%)     192 (75%)                     131 (84.5%)     **0.023**
  Age (n = 411) (years)                                40 (34; 48)     40 (34; 46)                   50 (33; 49)     0.488
  Caucasian origin (n = 394) (%)                       317 (80.5%)     187 (75.7%)                   130 (88.4%)     **0.002**
  Time since HIV diagnosis (n = 411) (years)           1 (1; 1)        1 (1; 1)                      1 (1; 1)        0.517
  CD4^+^ cell count at baseline (n = 411) (cells/μL)   104 (41; 159)   92.7 (38; 157)                115 (47; 162)   0.198
  Hepatitis C infection (n = 411) (%)                  32 (7.8%)       23 (9%)                       9 (5.8%)        0.244
  Hepatitis B infection (n = 411) (%)                  20 (4.9%)       14 (5.5%)                     6 (3.9%)        0.466
  cART regimen (n = 411) (%)                                                                                         0.054
  PI-based                                             127 (31%)       73 (28.5%)                    54 (35.1%)      
  NNRTI-based                                          205 (50%)       134 (52.3%)                   71 (46.1%)      
  PI+NNRTI-based                                       53 (12.9%)      38 (14.8%)                    15 (9.7%)       
  Others                                               25 (6.1%)       11 (4.4%)                     14 (9.1%)       
  HIV transmission route (n = 384) (%)                                                                               0.079
  Homosexual transmission                              189 (49.2%)     106 (45.1%)                   83 (55.7%)      
  Heterosexual transmission                            139 (36.2%)     95 (40.4%)                    44 (29.5%)      
  IDU                                                  56 (14.6%)      34 (14.5%)                    22 (14.8%)      

Statistical: Values were expressed as absolute number (percentage) and median (percentile 25; percentile 75). Significant differences are shown in bold. The percentages were calculated with respect to the available values, which are indicated in the left column in parentheses. *p*-values were calculated by Chi-square and Mann--Whitney tests. Abbreviations: IDU, intravenous drug users; HIV, Human immunodeficiency virus; cART, combination antiretroviral therapy; PI, HIV protease inhibitor; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor.
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###### 

Summary of the CD4^+^ T-cells recovery according to *IL7RA* rs6897932 polymorphism in HIV-infected patients who started combination antiretroviral therapy with very low CD4^+^ T-cells count (\<200 cells/mm^3^).

  Outcomes                           rs6897932 Genotypes ^(^\*^)^   Unadjusted Analysis ^(^\*^)^   Adjusted Analysis ^(^\*\*^)^                                                             
  ---------------------------------- ------------------------------ ------------------------------ ------------------------------ ------------- ----------- ------------------- ----------- -----------
  Slope CD4^+^ recovery              9.1 (5.9; 12.9)                10.3 (6.1; 14.8)               1.12 (0.99; 1.28)              0.070         0.070       1.16 (1.03; 1.31)   **0.016**   0.028
  ≥10 CD4^+^ cells/mm^3^ per month   105 (41%)                      82 (52.9%)                     1.61 (1.08; 2.41)              **0.019**     **0.044**   1.75 (1.14; 2.69)   **0.010**   **0.028**
  ≥15 CD4^+^ cells/mm^3^ per month   38 (14.8%)                     37 (23.9%)                     1.79 (1.08; 2.88)              **0.023**     **0.044**   1.94 (1.14; 3.30)   **0.015**   **0.028**
  CD4^+^ increase (ΔCD4^+^)          258 (167; 381)                 295 (189; 442)                 1.15 (1.02; 1.31)              **0.020**     **0.044**   1.19 (1.06; 1.34)   **0.004**   **0.022**
  ≥200 CD4^+^ cells/mm^3^            164 (64.1%)                    114 (73.5%)                    1.56 (1.01; 2.42)              **0.047**     0.054       1.63 (1.03; 2.57)   **0.036**   **0.044**
  ≥300 CD4^+^ cells/mm^3^            97 (37.9%)                     75 (44.8%)                     1.53 (1.03; 2.30)              **0.037**     0.051       1.63 (1.06; 2.49)   **0.025**   **0.034**
  ≥400 CD4^+^ cells/mm^3^            54 (21.1%)                     48 (31%)                       1.67 (1.06; 2.64)              **0.025**     **0.044**   1.63 (1.01; 2.63)   **0.047**   0.052
  ≥500 CD4^+^ cells/mm^3^            24 (9.4%)                      26 (16.8%)                     1.94 (1.06; 3.53)              **0.028**     **0.044**   2.16 (1.14; 4.11)   **0.018**   **0.028**
  CD4^+^ at the end of follow-up     362 (260; 463)                 425 (274; 558)                 1.14 (1.03; 1.25)              **0.009**     **0.044**   1.13 (1.03; 1.24)   **0.006**   **0.022**
  ≥350 CD4^+^ cells/mm^3^            133 (52%)                      96 (61%)                       1.51 (1.01; 2.26)              **0.049**     0.054       1.51 (0.96; 2.37)   0.077       0.077
  ≥500 CD4^+^ cells/mm^3^            52 (20.3%)                     59 (38.1%)                     2.41 (1.54; 3.76)              **\<0.001**   **0.001**   2.44 (1.49; 3.99)   **0.006**   **0.022**

Statistical: (\*) Values were expressed as absolute number (percentage) and median (percentile 25; percentile 75). (\*\*), *p*-values were calculated by univariate regression or multivariate regression adjusted by the most important clinical and epidemiological characteristics (see statistical analysis section). *p*-values, raw *p*-values; *q*-values, *p*-values corrected for multiple testing using the false discovery rate (FDR) with the Benjamini and Hochberg procedure. The statistically significant differences are shown in bold. Significant differences are shown in bold. Abbreviations: Exp(B), exponentiation of the B coefficient, which was an arithmetic mean ratio (AMR) for continuous variable and an odds ratio (OR) for categorical variables; 95%CI, 95% of confidence interval; *p*-value, level of significance; HIV, human immunodeficiency virus; aAMR, adjusted arithmetic mean ratio; IL7RA, interleukin 7 receptor α-chain.

[^1]: Norma Rallón and José M. Benito contributed equally to this work.

[^2]: The clinical centers and research groups that contribute to CoRIS are shown in [Appendix A](#app2-biomolecules-09-00233){ref-type="app"}.
